TKT Announces Date of Second Quarter 2001 Financial Results and Conference Call
CAMBRIDGE, Mass., Jul 20, 2001 /PRNewswire via COMTEX/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX chart, msgs) will release second quarter 2001 financial results on Tuesday, July 31, 2001 after the close of U.S. financial markets. In connection with this announcement, TKT will host a conference call and live audio webcast on Tuesday, July 31, 2001 at 5:00 pm EDT.
Participants may access the call by dialing 706-679-4323 and referencing access code 1379142. This call will also be broadcast live over the Internet at www.tktx.com under the Investor Information section. Please dial in 5 to 10 minutes prior to the scheduled conference call time or log on to the website at least 15 minutes prior to the call in order to register, download, and install any necessary software.
The conference call will be archived on the Internet for approximately 72 hours for those who are unable to hear it live. A replay of the call will also be accessible by telephone after 7:00 pm EDT Tuesday, July 31, 2001 through midnight EDT on Friday, August 3, 2001. To replay the call, dial 706- 645-9291 using access code 1379142.
Transkaryotic Therapies, Inc. (TKT) is a biopharmaceutical company dedicated to the development and commercialization of products based on its three proprietary development platforms: Niche Protein(TM) products, Gene- Activated(R) proteins, and Gene Therapy. The Company's Niche Protein product platform is based on protein replacement for the treatment of rare genetic diseases, a group of disorders characterized by the absence of certain metabolic enzymes. TKT's gene activation technology is a proprietary approach to the large-scale production of therapeutic proteins, which does not require the cloning of genes and their subsequent insertion into non-human cell lines. The Company's Gene Therapy technology, known as Transkaryotic Therapy(TM), is focused on the commercialization of non-viral, ex vivo gene therapy products for the long-term treatment of chronic protein deficiency states.
Gene-Activated(R) is a registered trademark and Niche Protein(TM), TKT(TM), and Transkaryotic Therapy(TM) are trademarks of Transkaryotic Therapies, Inc.
Please visit our web site at www.tktx.com for additional information about Transkaryotic Therapies, Inc.
CONTACT:
Justine E. Koenigsberg
Director, Corporate Communications
(617) 349-0271
Source: Transkaryotic Therapies, Inc.
Contact:
Justine E. Koenigsberg, Director, Corporate Communications of
Transkaryotic Therapies, Inc., +1-617-349-0271
/Photo: NewsCom: newscom.com
AP Archive: photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
/Company News On-Call: prnewswire.com
URL: tktx.com |
